|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2024―Sep―18 |
Harringtonine metabolites: 5'-de-O-methylharringtonine and cephalotaxine, targeting spike protein and TMPRSS2 to double block membrane fusion of SARS-CoV-2 and its variants |
Jiapan Gao, Shiling Hu, Xiaoyu Ma, Yuxiu Zhang, Bingxi Ren, Panpan Lei, et al. (+2) Weina Ma, Langchong He |
2 |
[GO] |
2024―Apr―12 |
Corrigendum to “The prophylaxis and treatment potential of supplements for COVID-19” [Eur. J. Pharmacol. 887 (15 November 2020) 173530] |
Adeleh Sahebnasagh, Fatemeh Saghafi, Razieh Avan, Amirhosein Khoshi, Masoud Khataminia, Mohammadreza Safdari, et al. (+3) Solomon Habtemariam, Hassan Rezai Ghaleno, Seyed Mohammad Nabavi |
3 |
[GO] |
2023―Sep―27 |
From cardiovascular system to brain, the potential protective role of mas receptors in COVID-19 infection. |
Pamela Cappelletti, Giovanna Gallo, Rachele Marino, Sakthimala Palaniappan, Massimo Corbo, Carmine Savoia, Marco Feligioni |
4 |
[GO] |
2023―Jan―30 |
The role of the glucocorticoid receptor and its impact on steroid response in moderate-severe COVID-19 patients |
Gestina Aliska, Nafrialdi Nafrialdi, Khie Chen Lie, Rianto Setiabudy, Andani Eka Putra, Indah Suci Widyahening, Alida Roswita Harahap |
5 |
[GO] |
2023―Jan―12 |
Risk of thromboembolic events in non-hospitalized COVID-19 patients: A systematic review |
Gaelle P. Massoud, Dana H. Hazimeh, Ghadir Amin, Wissam Mekary, Joanne Khabsa, Tarek Araji, et al. (+4) Souha Fares, Mathias Mericskay, George W. Booz, Fouad A. Zouein |
6 |
[GO] |
2022―Nov―15 |
Therapeutic role of N-acetyl cysteine (NAC) for the treatment and/or management of SARS-CoV-2-induced lung damage in hamster model |
Voddu Suresh, Padmanava Behera, Deepti Parida, Amlan Priyadarshee Mohapatra, Suraja Kumar Das, Sneha Kumari, et al. (+4) Kiran Avula, Amruta Mohapatra, Gulam Hussain Syed, Shantibhusan Senapati |
7 |
[GO] |
2022―Sep―17 |
Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function |
Sanaz Abbaspour-Aghdam, Ali Hazrati, Samaneh Abdolmohammadi-Vahid, Safa Tahmasebi, Jafar Mohseni, Hamed Valizadeh, et al. (+10) Mehdi Nadiri, Haleh Mikaeili, Armin Sadeghi, Mehdi Yousefi, Leila Roshangar, Behzad Nikzad, Farhad Jadidi-Niaragh, Hossein Samadi Kafil, Kosar Malekpour, Majid Ahmadi |
8 |
[GO] |
2022―Jul―31 |
Mast cells promote viral entry of SARS-CoV-2 via formation of chymase/spike protein complex |
Shuang Liu, Yasuyuki Suzuki, Erika Takemasa, Ryusuke Watanabe, Masaki Mogi |
9 |
[GO] |
2022―May―23 |
Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019 |
Hossein Khorramdelazad, Mohammad Hossein Kazemi, Maryam Azimi, Azin Aghamajidi, Ali Zarezadeh Mehrabadi, Faezeh Shahba, et al. (+4) Nazanin Aghamohammadi, Reza Falak, Fatemeh Faraji, Reza Jafari |
10 |
[GO] |
2021―Dec―02 |
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial |
Mojtaba Shohan, Roohangiz Nashibi, Mohammad-Reza Mahmoudian-Sani, Farhad Abolnezhadian, Mehri Ghafourian, Seyed Mohammad Alavi, et al. (+2) Asaad Sharhani, Ali Khodadadi |
11 |
[GO] |
2021―Oct―21 |
Use of steroids in COVID-19 patients: A meta-analysis |
Manisha Thakur, Ashok Kumar Datusalia, Anoop Kumar |
12 |
[GO] |
2021―Oct―21 |
Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review |
Elnaz Khani, Sajad Khiali, Samineh Beheshtirouy, Taher Entezari-Maleki |
13 |
[GO] |
2021―Oct―02 |
Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms |
Zinnet Şevval Aksoyalp, Dilara Nemutlu-Samur |
14 |
[GO] |
2021―Jul―22 |
SARS-CoV-2 attenuates corticosteroid sensitivity by suppressing DUSP1 expression and activating p38 MAPK pathway |
Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Shirin Hafezi, Rasha Assiri, Saleh Al-Muhsen, et al. (+2) Qutayba Hamid, Rabih Halwani |
15 |
[GO] |
2021―Jul―07 |
Effects of antiviral drug therapy on dynamic thiol/disulphide homeostasis and nitric oxide levels in COVID-19 patients |
Ayşe Özlem Mete, Kübra Koçak, Ahmet Saracaloglu, Seniz Demiryürek, Özgür Altınbaş, Abdullah T. Demiryürek |
16 |
[GO] |
2021―Jun―12 |
Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies |
Kiarash Saleki, Shakila Yaribash, Mohammad Banazadeh, Ehsan Hajihosseinlou, Mahdi Gouravani, Amene Saghazadeh, Nima Rezaei |
17 |
[GO] |
2021―Jun―07 |
Efficacy and safety of Dihydroorotate dehydrogenase (DHODH) inhibitors “Leflunomide” and “Teriflunomide” in Covid-19: A narrative review. |
Hardeep Kaur, Phulen Sarma, Anusuya Bhattacharyya, Saurabh Sharma, Neeraj Chhimpa, Manisha Prajapat, et al. (+7) Ajay Prakash, Subodh Kumar, Ashutosh Singh, Rahul Singh, Pramod Avti, Prasad Thota, Bikash Medhi |
18 |
[GO] |
2021―May―17 |
Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment |
Abdolkarim Hosseini, Hadi Esmaeili Gouvarchin Ghaleh, Hossein Aghamollaei, Mahdi Fasihi Ramandi, Gholamhossein Alishiri, Alireza Shahriary, et al. (+3) Kazem Hassanpour, Mahdi Tat, Gholamreza Farnoosh |
19 |
[GO] |
2021―May―17 |
Azithromycin: Immunomodulatory and Antiviral Properties for SARS-CoV-2 Infection |
Mohammad Rafi Khezri, Naime Majidi Zolbanin, Morteza Ghasemnejad-berenji, Reza Jafari |
20 |
[GO] |
2021―May―15 |
Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity |
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Yaaser Q. Almulaiky, Natália Cruz-Martins, Gaber El-Saber Batiha |
21 |
[GO] |
2021―Apr―03 |
Virtual high throughput screening: Potential Inhibitors for SARS-CoV-2 PLPRO and 3CLPRO Proteases |
Dhananjay Jade, Selvaraj Ayyamperumal, Vyshnavi Tallapaneni, Chandrasekar Moola Joghee Nanjan, Sagar Barge, Surender Mohan, Moola Joghee Nanjan |
22 |
[GO] |
2021―Mar―13 |
COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not |
Morry Silberstein |
23 |
[GO] |
2021―Mar―02 |
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19 |
Bertram Pitt, Nadia R. Sutton, Zhong Wang, Sascha N. Goonewardena, Michael Holinstat |
24 |
[GO] |
2021―Feb―25 |
Brief review on repurposed drugs and vaccines for possible treatment of COVID-19 |
Priyasha De, Ishita Chakraborty, Bhargavi Karna, Nirmal Mazumder |
25 |
[GO] |
2021―Feb―17 |
No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial |
Hamidreza Jamaati, Seyed MohammadReza Hashemian, Behrooz Farzanegan, Majid Malekmohammad, Payam Tabarsi, Majid Marjani, et al. (+12) Afshin Moniri, Zahra Abtahian, Sara Haseli, Esmaeil Mortaz, Alireza Dastan, Abdolreza Mohamadnia, Abdolbaset Vahedi, Fatemeh Monjazebi, Fatemeh Yassari, Lida Fadaeizadeh, Ali Saffaei, Farzaneh Dastan |
26 |
[GO] |
2021―Feb―04 |
Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis |
Afra Rezagholizadeh, Sajad Khiali, Parvin Sarbakhsh, Taher Entezari-Maleki |
27 |
[GO] |
2021―Feb―03 |
Chloroquine: autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? |
Pawan Sharma, Kielan D. McAlinden, Saeid Ghavami, Deepak A. Deshpande |
28 |
[GO] |
2021―Feb―03 |
COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes |
Mohammad A.I. Al-Hatamleh, Ma’mon M. Hatmal, Walhan Alshaer, Engku Nur Syafirah E.A. Rahman, Manali Haniti Mohd-Zahid, Dina M. Alhaj-Qasem, et al. (+8) Chan Yean Yean, Iskandar Z. Alias, Juhana Jaafar, Khalid Ferji, Jean-Luc Six, Vuk Uskoković, Hiroshi Yabu, Rohimah Mohamud |
29 |
[GO] |
2021―Feb―02 |
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study |
Krishnaprasad Baby, Swastika Maity, Chetan H. Mehta, Akhil Suresh, Usha Y. Nayak, Yogendra Nayak |
30 |
[GO] |
2021―Jan―27 |
Association of ACE inhibitors and Angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study |
R.A.H.U.L. Parit, S.R.I.D.H.A.R. Jayavel |
31 |
[GO] |
2021―Jan―23 |
Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2 |
Shuai Ge, Xiangjun Wang, Yajing Hou, Yuexin Lv, Cheng Wang, Huaizhen He |
32 |
[GO] |
2021―Jan―20 |
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment |
Parastoo Tarighi, Samane Eftekhari, Milad Chizari, Mahsa Sabernavaei, Davod Jafari, Parastoo Mirzabeigi |
33 |
[GO] |
2021―Jan―10 |
Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic |
Sobia Noreen, Irsah Maqbool, Asadullah Madni |
34 |
[GO] |
2020―Dec―31 |
Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations |
Aditya K. Padhi, Aniruddha Seal, Javed Masood Khan, Maqusood Ahamed, Timir Tripathi |
35 |
[GO] |
2020―Dec―18 |
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel |
Zheng Zequn, W.U. Yujia, Q.I.A.N. Dingding, L.I.A.N. Jiangfang |
36 |
[GO] |
2020―Dec―01 |
Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): in silico analysis |
Bilal Çakır, Betül Okuyan, Göksel Şener, Tuğba Tunalı-Akbay |
37 |
[GO] |
2020―Dec―01 |
Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach |
Abida Batool, Nousheen Bibi, Farhat Amin, Mohammad Amjad Kamal |
38 |
[GO] |
2020―Nov―27 |
Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2) |
Chaima Mouffouk, Soumia Mouffouk, Sara Mouffouk, Leila Hambaba, Hamada Haba |
39 |
[GO] |
2020―Nov―25 |
COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies |
Kajal Rawat, Puja Kumari, Lekha Saha |
40 |
[GO] |
2020―Nov―20 |
A Comprehensive Review on Potential Therapeutics Interventions for COVID-19 |
Heerak Chugh, Amardeep Awasthi, Yashi Agarwal, Rajesh K. Gaur, Gagan Dhawan, Ramesh Chandra |
41 |
[GO] |
2020―Nov―20 |
A Review on Possible Mechanistic Insights of Nitazoxanide for Repurposing in COVID-19 |
Amit S. Lokhande, Padma V. Devarajan |
42 |
[GO] |
2020―Nov―20 |
An overview of viruses discovered over the last decades and drug development for the current Pandemic |
Agha Zeeshan Mirza, Hina Shamshad, Faisal Abdulrhman Osra, Turki M. Habeebullah, Moataz Morad |
43 |
[GO] |
2020―Nov―06 |
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19 |
Himanshu G. Toor, Devjani I. Banerjee, Soumya Lipsa Rath, Siddhi A. Darji |
44 |
[GO] |
2020―Nov―03 |
Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead |
Harmanjit Singh, Prerna Chauhan, Ashish Kumar Kakkar |
45 |
[GO] |
2020―Nov―01 |
Functional and druggability analysis of the SARS-CoV-2 proteome |
Claudio N. Cavasotto, Maximiliano Sánchez Lamas, Julián Maggini |
46 |
[GO] |
2020―Oct―31 |
COVID-19 and antimalarials. Have we been doing it wrong all along? |
Cismaru Cosmin Andrei, Cismaru Gabriel Laurentiu, Nabavi Seyed Fazel, Nabavi Seyed Mohammad, Berindan-Neagoe Ioana |
47 |
[GO] |
2020―Oct―29 |
Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies |
Pooja M, Gangavaram Jyothi Reddy, Kanipakam Hema, Sujatha Dodoala, Bharathi Koganti |
48 |
[GO] |
2020―Oct―29 |
In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain |
Nouredine Behloul, Sarra Baha, Yuqian Guo, Zhifang Yang, Ruihua Shi, Jihong Meng |
49 |
[GO] |
2020―Oct―29 |
Science unites a troubled world: Lessons from the pandemic |
George W. Booz, Fouad A. Zouein |
50 |
[GO] |
2020―Oct―24 |
Recent progress of antiviral therapy for coronavirus disease 2019 |
Mengmeng Zhao, Jishou Zhang, Hanli Li, Zhen Luo, Jing Ye, Yao Xu, et al. (+6) Zhen Wang, Di Ye, Jianfang Liu, Dan Li, Menglong Wang, Jun Wan |
51 |
[GO] |
2020―Oct―24 |
Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 Mpro using molecular docking and dynamics simulations studies |
Shahzaib Ahamad, Hema Kanipakam, Shweta Birla, Md Shaukat Ali, Dinesh Gupta |
52 |
[GO] |
2020―Oct―22 |
Gordian Knot: Gastrointestinal lesions caused by three highly pathogenic coronaviruses from SARS-CoV and MERS-CoV to SARS-CoV-2 |
Xiang Meng, Qiu-yue Lou, Wen-ying Yang, Ran Chen, Wen-hua Xu, Yang Yang, et al. (+3) Lei Zhang, Tao Xu, Hui-fen Xiang |
53 |
[GO] |
2020―Oct―21 |
Translating bioactive peptides for COVID-19 therapy |
Khushwant S. Bhullar, Steven J. Drews, Jianping Wu |
54 |
[GO] |
2020―Oct―18 |
Renin angiotensin system at the interface of COVID-19 infection |
Rukhsana Gul, Kim Uh-Hyun, Assim A. Alfadda |
55 |
[GO] |
2020―Oct―13 |
Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic |
Ranjana Bhandari, Garima Khanna, Anurag Kuhad |
56 |
[GO] |
2020―Oct―13 |
Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2 |
Shaik Mahammad Nayeem, Ershad Mohammed Sohail, Gajjela Priyanka Sudhir, Munnangi Srinivasa Reddy |
57 |
[GO] |
2020―Oct―11 |
Treatment for COVID-19: An overview |
Cristina Stasi, Silvia Fallani, Fabio Voller, Caterina Silvestri |
58 |
[GO] |
2020―Oct―07 |
Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review |
Akram Yarmohammadi, Mostafa Yarmohammadi, Sajad Fakhri, Haroon Khan |
59 |
[GO] |
2020―Oct―06 |
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment |
Yan Wang, Lei Chen |
60 |
[GO] |
2020―Oct―04 |
Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19? |
Luis H.A. Costa, Bruna M. Santos, Luiz G.S. Branco |
61 |
[GO] |
2020―Oct―01 |
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19 |
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa |
62 |
[GO] |
2020―Sep―22 |
Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19 |
Tania Islam, Md Rezanur Rahman, Busra Aydin, Hande Beklen, Kazim Yalcin Arga, Md Shahjaman |
63 |
[GO] |
2020―Sep―19 |
A review of medications used to control and improve the signs and symptoms of COVID-19 patients |
Kiavash Hushmandi, Saied Bokaie, Mehrdad Hashemi, Ebrahim Rahmani Moghadam, Mehdi Raei, Farid Hashemi, et al. (+3) Mahdi Bagheri, Solomon Habtemariam, Seyed Mohammad Nabavi |
64 |
[GO] |
2020―Sep―15 |
Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients |
Rui Huang, Chuanwu Zhu, Leyang Xue, Chunyang Li, Xiaomin Yan, Songping Huang, et al. (+18) Biao Zhang, Li Zhu, Tianmin Xu, Fang Ming, Yun Zhao, Juan Cheng, Huaping Shao, Xiang-an Zhao, Dawen Sang, Haiyan Zhao, Xinying Guan, Xiaobing Chen, Yuxin Chen, Jie Wei, Rahma Issa, Longgen Liu, Xuebing Yan, Chao Wu |
65 |
[GO] |
2020―Sep―15 |
Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic |
Faezeh Monji, Abrar Al-Mahmood Siddiquee, Farshad Hashemian |
66 |
[GO] |
2020―Sep―12 |
Possibility of magnesium supplementation for supportive treatment in patients with COVID-19 |
Chuan-Feng Tang, Hong Ding, Rui-Qing Jiao, Xing-Xin Wu, Ling-Dong Kong |
67 |
[GO] |
2020―Sep―12 |
COVID-19 associated complications and potential therapeutic targets. |
Jasmin D. Monpara, Srushti J. Sodha, Pardeep K. Gupta |
68 |
[GO] |
2020―Sep―12 |
Curcumin, a traditional spice component, can hold the promise against COVID-19? |
Vivek Kumar Soni, Arundhati Mehta, Yashwant Kumar Ratre, Atul Kumar Tiwari, Ajay Amit, Rajat Pratap Singh, et al. (+4) Subash Chandra Sonkar, Navaneet Chaturvedi, Dhananjay Shukla, Naveen Kumar Vishvakarma |
69 |
[GO] |
2020―Sep―11 |
Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 |
Upinder Kaur, Kumudini Acharya, Ritwick Mondal, Amit Singh, Luciano Saso, Sasanka Chakrabarti, Sankha Shubhra Chakrabarti |
70 |
[GO] |
2020―Sep―11 |
Macrophage responses associated with COVID-19: A pharmacological perspective |
George W. Booz, Raffaele Altara, Ali H. Eid, Zena Wehbe, Souha Fares, Hassan Zaraket, et al. (+2) Nada J. Habeichi, Fouad A. Zouein |
71 |
[GO] |
2020―Sep―01 |
The prophylaxis and treatment potential of supplements for COVID-19 |
Adeleh Sahebnasagh, Fatemeh Saghafi, Razieh Avan, Amirhosein Khoshi, Masoud Khataminia, Mohammadreza Safdari, et al. (+3) Solomon Habtemariam, Hassan Rezai Ghaleno, Seyed Mohammad Nabavi |
72 |
[GO] |
2020―Aug―22 |
Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. |
Nousheen Bibi, Sana Gul, Johar Ali, Mohammad Amjad Kamal |
73 |
[GO] |
2020―Aug―22 |
Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2 |
Ashkan Madadlou |
74 |
[GO] |
2020―Aug―20 |
Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial |
Daryoush Hamidi Alamdari, Ahmad Bagheri Moghaddam, Shahram Amini, Mohammad Reza Keramati, Azam Moradi Zarmehri, Aida Hamidi Alamdari, et al. (+4) Mohammadamin Damsaz, Hamed Banpour, Amir Yarahmadi, George Koliakos |
75 |
[GO] |
2020―Aug―15 |
The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis |
Parham Habibzadeh, Mohammad Mofatteh, Saeid Ghavami, Jamshid Roozbeh |
76 |
[GO] |
2020―Aug―08 |
What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results |
Vanessa Aparecida Marcolino, Tatiana Colombo Pimentel, Carlos Eduardo Barão |
77 |
[GO] |
2020―Aug―06 |
COVID-19: A review of the proposed pharmacological treatments |
Sarah Lam, Andrew Lombardi, Aviv Ouanounou |
78 |
[GO] |
2020―Aug―06 |
In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2 |
Balaji Gowrivel Vijayakumar, Deepthi Ramesh, Annu Joji, Jayadharini Jayachandra prakasan, Tharanikkarasu Kannan |
79 |
[GO] |
2020―Aug―05 |
Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective |
Suliman Khan, Huseyin Tombuloglu, Sameh E. Hassanein, Surya Rehman, Ayhan Bozkurt, Emre Cevik, et al. (+4) Shaimaa Abdel-Ghany, Ghulam Nabi, Ashaq Ali, Hussein Sabit |
80 |
[GO] |
2020―Aug―04 |
Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations |
Alireza Paniri, Mohammad Mahdi Hosseini, Ahmad Rasoulinejad, Haleh Akhavan-Niaki |
81 |
[GO] |
2020―Aug―03 |
In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2 |
Rujuta R. Deshpande, Arpita Pandey Tiwari, Narendra Nyayanit, Manisha Modak |
82 |
[GO] |
2020―Aug―01 |
An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment |
Alexander V. Lopachev, Rogneda B. Kazanskaya, Anastasiya V. Khutorova, Tatiana N. Fedorova |
83 |
[GO] |
2020―Jul―31 |
Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection |
Gayathri Krishna, Vinod Soman Pillai, Mohanan Valiya Veettil |
84 |
[GO] |
2020―Jul―31 |
Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting |
Sourena Sharifkashani, Melika Arab Bafrani, Alireza Soltani Khaboushan, Marzieh Pirzadeh, Ali Kheirandish, Hanie Yavarpour_Bali, et al. (+3) Amirhossein Hessami, Amene Saghazadeh, Nima Rezaei |
85 |
[GO] |
2020―Jul―25 |
OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath |
Ankit Awasthi, Sukriti Vishwas, Leander Corrie, Rajesh Kumar, Rubiya Khursheed, Jaskiran Kaur, et al. (+11) Rajan Kumar, K.R. Arya, Monica Gulati, Bimlesh Kumar, Sachin Kumar Singh, Narendra Kumar Pandey, Sheetu Wadhwa, Pardeep Kumar, Bhupinder Kapoor, Rajneesh Kumar Gupta, Ankit Kumar |
86 |
[GO] |
2020―Jul―17 |
Virology, pathogenesis, diagnosis and in-line treatment of COVID-19 |
Pavan Kumar Samudrala, Pramod Kumar, Kamlesh Choudhary, Nagender Thakur, Gaurav Suresh Wadekar, Richa Dayaramani, et al. (+2) Mukta Agrawal, Amit Alexander |
87 |
[GO] |
2020―Jul―17 |
Advances in the possible treatment of COVID-19: A review. |
Pankaj Chibber, Syed Assim Haq, Irfan Ahmed, Nusrit Iqbal Andrabi, Gurdarshan Singh |
88 |
[GO] |
2020―Jul―15 |
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know? |
Antonio Vitiello, Francesco Ferrara |
89 |
[GO] |
2020―Jul―04 |
Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus |
Calvin A. Omolo, Nikki Soni, Victoria Oluwaseun Fasiku, Irene Mackraj, Thirumala Govender |
90 |
[GO] |
2020―Jun―30 |
Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19 |
Mohamed A. El-Missiry, Ziad M.A. El-Missiry, Azza I. Othman |
91 |
[GO] |
2020―Jun―27 |
Drug treatment of coronavirus disease 2019 (COVID-19) in China. |
Zhe Jin, Jing-Yi Liu, Rang Feng, Lu Ji, Zi-Li Jin, Hai-Bo Li |
92 |
[GO] |
2020―Jun―27 |
Current pharmacological treatments for SARS-COV-2: A narrative review |
Giulio Nittari, Graziano Pallotta, Francesco Amenta, Seyed Khosrow Tayebati |
93 |
[GO] |
2020―Jun―17 |
Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? |
Antoni Sureda, Javad Alizadeh, Seyed Fazel Nabavi, Ioana Berindan Neagoe, Cosmin Andrei Cismaru, Philippe Jeandet, et al. (+4) Marek J. Los, Emilio Clementi, Seyed Mohammad Nabavi, Saeid Ghavami |